Trials / Not Yet Recruiting
Not Yet RecruitingNCT07184385
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- StemCyte, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
Detailed description
This is a two-arm, multi-center, double-blind, randomized, placebo-controlled phase III study. A total of 60 subjects with post-COVID will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | REGENECYTE | HPC, Cord Blood |
| BIOLOGICAL | Placebo | Normal Saline |
Timeline
- Start date
- 2026-03-31
- Primary completion
- 2027-06-30
- Completion
- 2027-09-30
- First posted
- 2025-09-19
- Last updated
- 2025-09-23
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07184385. Inclusion in this directory is not an endorsement.